“Eli Lilly’s revenue boosted by jacking up cost of insulin for diabetics” is the title of a recent Marketwatch story: http://www.marketwatch.com/story/eli-lillys-revenue-boosted-by-higher-drug-prices-for-diabetics-2016-01-28
The company reported the fourth-quarter revenue increase Thursday, with sales of Humalog insulin, a short-acting insulin used by consumers with Type I and Type II diabetes, leading the company’s U.S. pharmaceutical revenues with a 20% increase. That growth was “driven by higher realized prices, and, to a lesser extent, increased volume,” the company said.
Lilly responded with an article in Forbes the next morning: http://www.forbes.com/sites/johnlechleiter/2016/01/28/ninety-year-old-lessons-for-biomedical-progress-today/#c8654d53cf72
Me? I remember being a new college student back in the 80’s when my part-time job easily let me pay for insulin - a whopping $7 a vial back then. No chance of that happening today.